The use of recombinant TRAIL or agonist antibodies targeting DR4 or DR5 alone to treat patients suffering from cancer is unlikely to translate to the clinic due to the poor ability of these agents to trigger sufficient apoptosis alone3,4. This evidence concerns the gene TNFRSF10B and cancer.